Huiyu Yuanhe

Huiyu Yuanhe is a biotechnology company based in Chengdu, China, operating as a specialized subsidiary of Huiyu Pharmaceutical. The company is dedicated to the discovery and development of innovative nucleic acid therapeutics, with a primary focus on small interfering RNA (siRNA) and mRNA-based drugs. Leveraging its proprietary delivery platforms, including GalNAc-conjugation and lipid nanoparticle (LNP) technologies, Huiyu Yuanhe targets high-prevalence conditions such as cardiovascular diseases, metabolic disorders, and oncology. Its lead candidate, HY-001, is an siRNA targeting Factor XI currently in Phase 1 clinical trials for the prevention of thrombosis. By combining the parent company's manufacturing expertise with cutting-edge genomic research, Huiyu Yuanhe aims to deliver long-acting, precision medicines to the global market.